Developer docs
API playgroundTry for free, no card

Search company profiles

Solasta Bio

Full company profile

uuid0000wsd

Namestring
Solasta Bio
Legal namestring
SOLASTA Bio Ltd.
Websiteurl
solastabio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Solasta Bio is a Glasgow-based agri-biotech company developing neuropeptide-based bioinsecticides as a sustainable alternative to conventional chemical insecticides for crop protection. Founded in 2021 as a spin-out from the University of Glasgow, the company engineers bio-inspired peptides designed to target specific pest insect groups with unique insect specificity, disrupting pest behavior and lifecycles — causing pests to forget to lay eggs or avoid feeding — while remaining non-toxic to non-targeted species including pollinators, wildlife, humans, and soil. The company has completed over 50 greenhouse and field trials across Asia, Europe, and the United States demonstrating efficacy at least comparable to traditional chemical insecticides, and has built a patent portfolio of 14 granted patents (8 in the US and 6 in Europe). The platform is regulated under nature-inspired peptide chemistry and has received an EPA green light, accelerating the path toward US regulatory approval.

The company is pre-commercial and does not yet generate product revenue. Its intended revenue model centers on commercial sales of peptide-based bioinsecticide products to growers and agricultural businesses, with first market entry targeted for 2027. Pricing has not been publicly disclosed. Solasta Bio is building distribution primarily through strategic channel partnerships with major agricultural input companies — FMC Ventures (FMC Corporation), Corteva Catalyst (Corteva, Inc.), and Cavallo Ventures (Wilbur-Ellis) — alongside a direct enterprise field-sales motion, anchored by a dedicated US operations base in North Carolina. Institutional investors backing the company include Forbion BioEconomy Fund (Series A lead), Yield Lab Europe, Rubio Impact Ventures, Scottish Enterprise, SIS Ventures, UKI2S, and Innovate UK (grant support), with total funding of approximately $19 million raised across seed (£1.3M, 2021), an undisclosed round (£4M, 2023), and Series A ($14M, December 2024).

As of late 2025, Solasta Bio operates from a 4,000+ square foot headquarters and laboratory facility at the West of Scotland Science Park in Glasgow and employs 26 people. The leadership team is anchored by academic co-founders CEO Shireen Davies and CSO Julian Dow, supplemented by experienced commercial executives including CFO David Armour, CSO Paula Pinto, and CBO Daphne Preuss (US operations). The company has been recognized in The Sunday Times 100 Tech "Ones to Watch" and as one of nine best UK agritech startups to watch in 2025.

Short descriptiontext

Solasta Bio is a Glasgow-based agri-biotech company developing neuropeptide-based bioinsecticides for precision-targeted crop protection. Founded in 2021 as a University of Glasgow spin-out, it serves commercial growers with sustainable pest control products expected to launch by 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGlasgow, United Kingdom
HQ citystring
Glasgow
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide-based bioinsecticides, crop protection solutions, agricultural biotechnology, insect pest control, biopesticide products
Industry2 codes
PRIMARYAFABAEAC
Microbial Bioinsecticides (incl. Bt)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAKAB
Biological Pest Control (Beneficial Insects, Nematodes, Microbials)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Organic & Regenerative Inputs (OMRI Inputs, Compost, Natural Pest Control)
NAICS code2 codes
  • Pesticide and Other Agricultural Chemical Manufacturing32532
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Agricultural Chemicals2870
Product category
Agricultural Biotechnology
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Peptide-based bioinsecticide products
TypeOne Time License
Description

The company plans to commercialize neuropeptide-based insect control products for crop protection. Products expected to reach market by 2027. Revenue model will likely involve product sales to growers and agri-businesses.

solastabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Solasta Bio develops nature-inspired, neuropeptide-based bioinsecticides that deliver precision-targeted pest control while protecting pollinators, wildlife, and non-targeted species. The peptides act on specific insect targets to alter behavior and disrupt lifecycles rather than killing outright, and are bio-degradable with no resistance build-up. The company is pre-commercial, with first products planned for market entry by 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Efficacy at least as effective as traditional chemical insecticides
+3 more records
Product overview1 text field

SOLASTA Bio offers a unified peptide-based bioinsecticide product platform under the SOLASTA® Bio Precision Insect Control brand. The company's solutions are nature-inspired neuropeptide-based products that target specific pest insects while being non-toxic to all non-targeted species including pollinators, wildlife, humans, and land. The products work by altering pest behavior and disrupting lifecycles rather than killing outright, and are designed to be environmentally friendly, cost-effective, and to prevent resistance build-up. The company plans to commercialize its first products by 2027.

Product and service1 record
1SOLASTA® Bio Precision Insect Control
CategoryBiopesticides / Crop Protection
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spin-out origin. CEO Shireen Davies and CSO Julian Dow were professors at University of Glasgow. Company developed from research in insect neuroendocrinology and 'omics.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solasta Bio

Agricultural Biotechnologysolastabio.com

Solasta Bio is a Glasgow-based agri-biotech company developing neuropeptide-based bioinsecticides for precision-targeted crop protection. Founded in 2021 as a University of Glasgow spin-out, it serves commercial growers with sustainable pest control products expected to launch by 2027.

What Solasta Bio does

Solasta Bio is a Glasgow-based agri-biotech company developing neuropeptide-based bioinsecticides as a sustainable alternative to conventional chemical insecticides for crop protection. Founded in 2021 as a spin-out from the University of Glasgow, the company engineers bio-inspired peptides designed to target specific pest insect groups with unique insect specificity, disrupting pest behavior and lifecycles — causing pests to forget to lay eggs or avoid feeding — while remaining non-toxic to non-targeted species including pollinators, wildlife, humans, and soil. The company has completed over 50 greenhouse and field trials across Asia, Europe, and the United States demonstrating efficacy at least comparable to traditional chemical insecticides, and has built a patent portfolio of 14 granted patents (8 in the US and 6 in Europe). The platform is regulated under nature-inspired peptide chemistry and has received an EPA green light, accelerating the path toward US regulatory approval.

The company is pre-commercial and does not yet generate product revenue. Its intended revenue model centers on commercial sales of peptide-based bioinsecticide products to growers and agricultural businesses, with first market entry targeted for 2027. Pricing has not been publicly disclosed. Solasta Bio is building distribution primarily through strategic channel partnerships with major agricultural input companies — FMC Ventures (FMC Corporation), Corteva Catalyst (Corteva, Inc.), and Cavallo Ventures (Wilbur-Ellis) — alongside a direct enterprise field-sales motion, anchored by a dedicated US operations base in North Carolina. Institutional investors backing the company include Forbion BioEconomy Fund (Series A lead), Yield Lab Europe, Rubio Impact Ventures, Scottish Enterprise, SIS Ventures, UKI2S, and Innovate UK (grant support), with total funding of approximately $19 million raised across seed (£1.3M, 2021), an undisclosed round (£4M, 2023), and Series A ($14M, December 2024).

As of late 2025, Solasta Bio operates from a 4,000+ square foot headquarters and laboratory facility at the West of Scotland Science Park in Glasgow and employs 26 people. The leadership team is anchored by academic co-founders CEO Shireen Davies and CSO Julian Dow, supplemented by experienced commercial executives including CFO David Armour, CSO Paula Pinto, and CBO Daphne Preuss (US operations). The company has been recognized in The Sunday Times 100 Tech "Ones to Watch" and as one of nine best UK agritech startups to watch in 2025.

Solasta Bio firmographics

Firmographics
Name
Solasta Bio
Legal name
SOLASTA Bio Ltd.
Website
https://solastabio.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Solasta Bio is a Glasgow-based agri-biotech company developing neuropeptide-based bioinsecticides for precision-targeted crop protection. Founded in 2021 as a University of Glasgow spin-out, it serves commercial growers with sustainable pest control products expected to launch by 2027.
Ownership category
akta.pro rank

Solasta Bio industry classification

Industry
Product category
Agricultural Biotechnology
NAICS
Pesticide and Other Agricultural Chemical Manufacturing (32532), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Agricultural Chemicals (2870)
akta.pro industry
PRIMARYAFABAEAC
Microbial Bioinsecticides (incl. Bt)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAKAB
Biological Pest Control (Beneficial Insects, Nematodes, Microbials)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Organic & Regenerative Inputs (OMRI Inputs, Compost, Natural Pest Control)

Keywords

  • Peptide-based bioinsecticides
  • Crop protection solutions
  • Agricultural biotechnology
  • Insect pest control
  • Biopesticide products

Where Solasta Bio is headquartered

Location

Headquarters

HQ city
Glasgow
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Solasta Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Peptide-based bioinsecticide products: The company plans to commercialize neuropeptide-based insect control products for crop protection. Products expected to reach market by 2027. Revenue model will likely involve product sales to growers and agri-businesses.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Solasta Bio product offering

Product offering

Core offering

Solasta Bio develops nature-inspired, neuropeptide-based bioinsecticides that deliver precision-targeted pest control while protecting pollinators, wildlife, and non-targeted species. The peptides act on specific insect targets to alter behavior and disrupt lifecycles rather than killing outright, and are bio-degradable with no resistance build-up. The company is pre-commercial, with first products planned for market entry by 2027.

Product overview

SOLASTA Bio offers a unified peptide-based bioinsecticide product platform under the SOLASTA® Bio Precision Insect Control brand. The company's solutions are nature-inspired neuropeptide-based products that target specific pest insects while being non-toxic to all non-targeted species including pollinators, wildlife, humans, and land. The products work by altering pest behavior and disrupting lifecycles rather than killing outright, and are designed to be environmentally friendly, cost-effective, and to prevent resistance build-up. The company plans to commercialize its first products by 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • SOLASTA® Bio Precision Insect Control

Quantifiable outcome

  • Efficacy at least as effective as traditional chemical insecticides
  • +3 more outcomes

Companies that use Solasta Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Solasta Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Solasta Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of GlasgowcoreStrategic or Co-development PartnerSpin-out origin. CEO Shireen Davies and CSO Julian Dow were professors at University of Glasgow. Company developed from research in insect neuroendocrinology and 'omics.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Solasta Bio competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Solasta Bio social profiles

Digital presence

Solasta Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solasta Bio leadership team

Management profile

Number of profiles

Profiles14 records

Solasta Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solasta Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solasta Bio

What does Solasta Bio do?

Solasta Bio develops nature-inspired, neuropeptide-based bioinsecticides that deliver precision-targeted pest control while protecting pollinators, wildlife, and non-targeted species. The peptides act on specific insect targets to alter behavior and disrupt lifecycles rather than killing outright, and are bio-degradable with no resistance build-up. The company is pre-commercial, with first products planned for market entry by 2027.

Is Solasta Bio a public or private company?

Solasta Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Solasta Bio founded?

Solasta Bio was founded in 2021. It employs 11 to 50 people.

Where is Solasta Bio based?

Solasta Bio is headquartered in Glasgow, United Kingdom, in the Europe region.

How does Solasta Bio make money?

One revenue line is on record: peptide-based bioinsecticide products.

Does Solasta Bio have an API?

No public API is recorded for Solasta Bio.

What industry is Solasta Bio in?

Solasta Bio's product category is Agricultural Biotechnology. Its primary akta.pro industry code is AFABAEAC, Microbial Bioinsecticides (incl. Bt), with a secondary code of AFABAKAB, Biological Pest Control (Beneficial Insects, Nematodes, Microbials). Its NAICS code is 32532 and its SIC code is 2870.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaInsecticide firm hits US regulatory milestone - major step towards bringing tech to marketSOLASTA Bio submitted its lead aphid peptide product to the US EPA and California regulators, a first registration step. The peptide, classified as biochemical, targets aphids and whiteflies with a benign ecotoxicology profile. The company seeks IRAC recognition as a new mode of action.EIN PresswireSOLASTA® Bio hits US regulatory milestone as field demo beats decade-high whitefly surgeSOLASTA Bio submitted its first US regulatory package for an aphid-targeting peptide product, with concurrent review by EPA and CDPR. The company's field demo in Georgia showed visible reductions in leaf-feeding damage despite a decade-high whitefly surge. The lead product will focus on aphid control in leafy greens and vegetable crops.EIN PresswireSOLASTA® Bio hits US regulatory milestone as field demo beats decade-high whitefly surgeSOLASTA Bio submitted its first US regulatory package for an aphid-targeting peptide product, with concurrent review by EPA and CDPR. The company's field demo in Georgia showed visible reductions in leaf-feeding damage despite a decade-high whitefly surge. The lead product will focus on aphid control in leafy greens and vegetable crops.Business & FinancialSOLASTA® Bio Hits US Regulatory Milestone As Field Demo Beats Decade-High Whitefly SurgeSOLASTA Bio submitted its first US regulatory package for an aphid-targeting peptide product, with concurrent review by EPA and CDPR. The company's field demo in Georgia showed visible reductions in leaf-feeding damage despite a decade-high whitefly surge. The lead peptide is classified as biochemical, offering a faster regulatory pathway.Scotland NewsSolasta Bio hails 'paradigm shift' in crop protectionGlasgow-based biotech company Solasta Bio has announced that its nature-inspired peptide insecticides demonstrated at least 85% efficacy in over 50 greenhouse and field trials across Asia, the US, and Europe, while leaving beneficial insects such as bees unharmed. The company has been granted 14 patents (8 in the US, 6 in Europe) and is transitioning to its own dedicated facility in the West of Scotland Science Park as it advances toward commercialization. Solasta Bio, a spin-out from the University of Glasgow founded in 2021, has raised £14.5 million in equity investment to date, including an oversubscribed £10.7m funding round led by Forbion with FMC Ventures and Corteva Catalyst.Scotland NewsSolasta graduates to commercial facilities in GlasgowSolasta Bio, a biotech company developing nature-inspired green insecticides, has moved into new commercial facilities at the West of Scotland Science Park in Glasgow, marking a major growth milestone since its founding at the University of Glasgow in 2021. The company, which now employs 26 staff across 4,000 sq ft of custom-fitted laboratory and office space, has been supported by a £190,000 Scottish Enterprise grant and has raised £14.5 million in equity investment, including an oversubscribed £10.7m funding round led by Forbion. The move positions Solasta to accelerate R&D and commercialization, with its lead peptide candidates having received favorable classification from the US Environmental Protection Agency, exempting products from conventional insecticide registration in the $8bn US market.SolastabioBetter for your crops. Vital for our planet.SOLASTA Bio has developed a next-generation biotechnology solution for crop protection that uses precision-targeted peptides to control specific insect pests without harming non-target species. The company claims its bio-safe and biodegradable products offer efficacy comparable to traditional chemical insecticides while protecting essential pollinators and the environment. This approach aims to address global challenges in food security and sustainable farming by providing a safer alternative to toxic pesticides.BusinessCloud£10.7m to grow green insecticide AgriTech firmSOLASTA Bio raised £10.7m in a Series A round led by Forbion to accelerate its green insecticide development. The Glasgow firm's nature-inspired platform targets pests while protecting pollinators, with field trials showing efficacy on par with commercial standards. The company targets market entry by 2027.GlobeNewswireSOLASTA Bio Completes $14m Series A to Accelerate Nature-Inspired Crop ProtectionSOLASTA Bio completed an oversubscribed $14 million Series A round led by Forbion, with co-leads from FMC Ventures and Corteva Catalyst. The funding will accelerate its peptide-based bioinsecticides, targeting a $27 billion market and market entry by 2027.FinSMEsSolasta Bio Closes $14M Series A FundingSolasta Bio, a UK agri-biotech firm, raised $14M in Series A funding led by Forbion, FMC Ventures, and Corteva Catalyst. The round brings total funding to $19M, to accelerate peptide-based bioinsecticide development. The company's platform targets insect pests while protecting pollinators.